Classen Immunotherapies v. Biogen IDEC — Federal Circuit Addresses § 101 for Vaccination Scheduling Method Claims
The Federal Circuit held that Classen Immunotherapies’ method claims for identifying optimal vaccination schedules to reduce chronic immune-mediated disorders were patent-eligible under § 101 in part — distinguishing between claims that merely require correlating a natural relationship and cla